Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COXFA4 | O00483 | 2/20 | 0.67 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.56 |
| ▸ | ODC1 | P11926 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 12/20 | 0.47 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12315561 | 1.00 | COXFA4 (0.67) | COXFA4HSP90AA1ODC1HIF1AEPAS1 | |
| SCHEMBL4432821 | 1.00 | COXFA4 (0.67) | COXFA4HSP90AA1ODC1HIF1AEPAS1 | |
| SCHEMBL12315565 | 0.90 | COXFA4 (0.64) | COXFA4HSP90AA1ODC1HIF1AEPAS1 | |
| SCHEMBL14666256 | 0.86 | COXFA4 (0.51) | COXFA4HSP90AA1HIF1AEPAS1 | |
| SCHEMBL12315552 | 0.86 | COXFA4 (0.74) | COXFA4HSP90AA1HIF1A | |
| SCHEMBL12315460 | 0.84 | COXFA4 (0.67) | COXFA4HSP90AA1ODC1HIF1AEPAS1 | |
| SCHEMBL3457889 | 0.83 | COXFA4 (0.56) | COXFA4HSP90AA1ODC1HIF1AEPAS1 | |
| SCHEMBL3457885 | 0.83 | COXFA4 (0.56) | COXFA4HSP90AA1ODC1HIF1AEPAS1 | |
| SCHEMBL14139182 | 0.82 | COXFA4 (0.65) | COXFA4HSP90AA1ODC1HIF1AEPAS1 | |
| SCHEMBL14139181 | 0.82 | COXFA4 (0.65) | COXFA4HSP90AA1ODC1HIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8263042-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20090104118-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | CITIZENS BANK, N.A. | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090104118-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | COXFA4 2119/4885HSP90AA1 1970/4885ODC1 4756/4885 |
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | COXFA4 2119/4885HSP90AA1 1970/4885ODC1 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.